# PMV Pharmaceuticals Inc. (PMVP)

Source: https://www.quantisnow.com/company/PMVP
Generated: 2026-11-12T23:22:34.213Z

- Ticker: PMVP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- SEC CIK: 0001699382
- Website: pmvpharma.com

## About

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

## Latest PMVP news and filings

- 2026-11-10 13:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pmv-pharmaceuticals-inc-6783042)
- 2026-11-10 13:00 UTC [SEC Form 8-K] [PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pmv-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6782994)
- 2026-11-10 13:00 UTC [Earnings] [PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights](https://www.quantisnow.com/insight/pmv-pharmaceuticals-reports-third-quarter-2026-financial-results-and-corporate-6782979)
- 2026-10-05 20:14 UTC [SEC Form 4] [SEC Form 4 filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-pmv-pharmaceuticals-inc-6736916)
- 2026-10-05 20:04 UTC [SEC Form 3] [SEC Form 3 filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-pmv-pharmaceuticals-inc-6736731)
- 2026-10-05 13:00 UTC [SEC Form 8-K] [PMV Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/pmv-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6736208)
- 2026-10-05 12:00 UTC [Leadership Update] [PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors](https://www.quantisnow.com/insight/pmv-pharmaceuticals-appoints-matt-eckler-phd-to-board-of-directors-6735964)
- 2026-09-08 12:00 UTC [Leadership Update] [PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer](https://www.quantisnow.com/insight/pmv-pharmaceuticals-appoints-philip-herman-as-chief-commercial-officer-6707517)
- 2026-09-01 03:03 UTC [Public Offering] [PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities](https://www.quantisnow.com/insight/pmv-pharma-announces-pricing-of-oversubscribed-50-million-public-offering-6700288)
- 2026-08-31 21:01 UTC [SEC Form 424B3] [SEC Form 424B3 filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-pmv-pharmaceuticals-inc-6700034)
- 2026-08-31 20:25 UTC [SEC Form 424B5] [SEC Form 424B5 filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-pmv-pharmaceuticals-inc-6699861)
- 2026-08-31 20:06 UTC [SEC Form 8-K] [SEC Form 8-K filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-pmv-pharmaceuticals-inc-6699728)
- 2026-08-31 20:02 UTC [Public Offering] [PMV Pharma Announces Proposed Public Offering of Securities](https://www.quantisnow.com/insight/pmv-pharma-announces-proposed-public-offering-of-securities-6699646)
- 2026-08-31 20:01 UTC [PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial](https://www.quantisnow.com/insight/pmv-pharmaceuticals-announces-updated-promising-rezatapopt-monotherapy-interim-ovarian-cancer-6699637)
- 2026-08-14 12:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pmv-pharmaceuticals-inc-6681887)
- 2026-08-14 12:00 UTC [SEC Form 8-K] [PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pmv-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6681884)
- 2026-08-14 12:00 UTC [PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights](https://www.quantisnow.com/insight/pmv-pharmaceuticals-reports-second-quarter-2026-financial-results-and-corporate-6681860)
- 2026-07-28 20:48 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pmv-pharmaceuticals-inc-6651977)
- 2026-07-10 15:40 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pmv-pharmaceuticals-inc-6633835)
- 2026-07-08 12:26 UTC [Analyst Coverage Initiated] [Ladenburg Thalmann initiated coverage on PMV Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/ladenburg-thalmann-initiated-coverage-on-pmv-pharmaceuticals-with-a-new-6630965)
- 2026-06-05 20:32 UTC [SEC Form 4] [SEC Form 4 filed by Director Stelzer Laurie](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stelzer-laurie-6591584)
- 2026-06-05 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Levine Arnold J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-levine-arnold-j-6591520)
- 2026-06-05 20:25 UTC [SEC Form 4] [SEC Form 4 filed by Director Gallagher Carol Giltner](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gallagher-carol-giltner-6591442)
- 2026-06-05 20:23 UTC [SEC Form 4] [SEC Form 4 filed by Director Flowers Kirsten](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-flowers-kirsten-6591422)
- 2026-06-05 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Baum Charles M](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-baum-charles-m-6591408)
- 2026-06-05 12:10 UTC [SEC Form 8-K] [SEC Form 8-K filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-pmv-pharmaceuticals-inc-6590579)
- 2026-05-15 20:05 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pmv-pharmaceuticals-inc-6557113)
- 2026-05-12 12:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pmv-pharmaceuticals-inc-6546784)
- 2026-05-12 12:00 UTC [SEC Form 8-K] [PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pmv-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6546778)
- 2026-05-04 20:14 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pmv-pharmaceuticals-inc-6529096)
- 2026-04-22 12:04 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-pmv-pharmaceuticals-inc-6509604)
- 2026-04-22 12:01 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-pmv-pharmaceuticals-inc-6509599)
- 2026-04-22 12:00 UTC [Leadership Update] [PMV Pharmaceuticals Announces Board Chair Transition](https://www.quantisnow.com/insight/pmv-pharmaceuticals-announces-board-chair-transition-6509519)
- 2026-03-09 20:41 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Carulli Michael](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-carulli-michael-6437614)
- 2026-03-09 20:39 UTC [SEC Form 4] [SEC Form 4 filed by General Counsel & COO Ticktin Robert](https://www.quantisnow.com/insight/sec-form-4-filed-by-general-counsel-coo-ticktin-robert-6437593)
- 2026-03-09 20:36 UTC [SEC Form 4] [SEC Form 4 filed by Chief Development Officer Jalota Deepika](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-development-officer-jalota-deepika-6437568)
- 2026-03-09 20:35 UTC [SEC Form 4] [SEC Form 4 filed by President and CEO Mack David Henry](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-and-ceo-mack-david-6437548)
- 2026-03-06 14:23 UTC [SEC Form S-8] [SEC Form S-8 filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-pmv-pharmaceuticals-inc-6434246)
- 2026-03-06 13:24 UTC [SEC Form 8-K] [PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pmv-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6434090)
- 2026-03-06 13:01 UTC [SEC Form 10-K] [SEC Form 10-K filed by PMV Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-pmv-pharmaceuticals-inc-6434038)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PMVP
- Earnings history: https://www.quantisnow.com/earnings/PMVP
- Dividend history: https://www.quantisnow.com/dividends/PMVP
- Insider transactions: https://www.quantisnow.com/insiders/PMVP
- Options chain: https://www.quantisnow.com/options/PMVP
- SEC 8-K filings only: https://www.quantisnow.com/company/PMVP/8-k
- RSS and alerts for PMVP: https://www.quantisnow.com/docs/rss-feeds.md